215 related articles for article (PubMed ID: 22336948)
1. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin.
Kanada KN; Nakatsuji T; Gallo RL
J Invest Dermatol; 2012 May; 132(5):1435-42. PubMed ID: 22336948
[TBL] [Abstract][Full Text] [Related]
2. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel.
Coda AB; Hata T; Miller J; Audish D; Kotol P; Two A; Shafiq F; Yamasaki K; Harper JC; Del Rosso JQ; Gallo RL
J Am Acad Dermatol; 2013 Oct; 69(4):570-7. PubMed ID: 23871720
[TBL] [Abstract][Full Text] [Related]
3.
Roh KB; Ryu DH; Cho E; Weon JB; Park D; Kweon DH; Jung E
Molecules; 2020 Nov; 25(23):. PubMed ID: 33256158
[TBL] [Abstract][Full Text] [Related]
4. Light-emitting diodes downregulate cathelicidin, kallikrein and toll-like receptor 2 expressions in keratinocytes and rosacea-like mouse skin.
Lee JB; Bae SH; Moon KR; Na EY; Yun SJ; Lee SC
Exp Dermatol; 2016 Dec; 25(12):956-961. PubMed ID: 27315464
[TBL] [Abstract][Full Text] [Related]
5. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin.
Yamasaki K; Schauber J; Coda A; Lin H; Dorschner RA; Schechter NM; Bonnart C; Descargues P; Hovnanian A; Gallo RL
FASEB J; 2006 Oct; 20(12):2068-80. PubMed ID: 17012259
[TBL] [Abstract][Full Text] [Related]
6. Kallikrein expression and cathelicidin processing are independently controlled in keratinocytes by calcium, vitamin D(3), and retinoic acid.
Morizane S; Yamasaki K; Kabigting FD; Gallo RL
J Invest Dermatol; 2010 May; 130(5):1297-306. PubMed ID: 20090765
[TBL] [Abstract][Full Text] [Related]
7. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea.
Yamasaki K; Di Nardo A; Bardan A; Murakami M; Ohtake T; Coda A; Dorschner RA; Bonnart C; Descargues P; Hovnanian A; Morhenn VB; Gallo RL
Nat Med; 2007 Aug; 13(8):975-80. PubMed ID: 17676051
[TBL] [Abstract][Full Text] [Related]
8. A Novel Mechanism of Carvedilol Efficacy for Rosacea Treatment: Toll-Like Receptor 2 Inhibition in Macrophages.
Zhang J; Jiang P; Sheng L; Liu Y; Liu Y; Li M; Tao M; Hu L; Wang X; Yang Y; Xu Y; Liu W
Front Immunol; 2021; 12():609615. PubMed ID: 34322115
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Human Kallikrein 5 Protease by Triterpenoids from Natural Sources.
Matsubara Y; Matsumoto T; Koseki J; Kaneko A; Aiba S; Yamasaki K
Molecules; 2017 Oct; 22(11):. PubMed ID: 29077044
[TBL] [Abstract][Full Text] [Related]
10. [New insights in the pathogenesis and treatment of rosacea].
Palatsi R; Kelhälä HL; Hägg P
Duodecim; 2012; 128(22):2327-35. PubMed ID: 23342479
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of cathelicidin by direct activation of protease-activated receptor 2: possible implications on the pathogenesis of rosacea.
Kim JY; Kim YJ; Lim BJ; Sohn HJ; Shin D; Oh SH
Yonsei Med J; 2014 Nov; 55(6):1648-55. PubMed ID: 25323904
[TBL] [Abstract][Full Text] [Related]
12. Epidermal proteases in the pathogenesis of rosacea.
Meyer-Hoffert U; Schröder JM
J Investig Dermatol Symp Proc; 2011 Dec; 15(1):16-23. PubMed ID: 22076323
[TBL] [Abstract][Full Text] [Related]
13. Kallikrein-related peptidase-8 (KLK8) is an active serine protease in human epidermis and sweat and is involved in a skin barrier proteolytic cascade.
Eissa A; Amodeo V; Smith CR; Diamandis EP
J Biol Chem; 2011 Jan; 286(1):687-706. PubMed ID: 20940292
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of proteolytic, serpinolytic, and progelatinase-b activation activities of periodontopathogens by doxycycline and the non-antimicrobial chemically modified tetracycline derivatives.
Grenier D; Plamondon P; Sorsa T; Lee HM; McNamara T; Ramamurthy NS; Golub LM; Teronen O; Mayrand D
J Periodontol; 2002 Jan; 73(1):79-85. PubMed ID: 11846203
[TBL] [Abstract][Full Text] [Related]
15. Improved clinical outcome and biomarkers in adults with papulopustular rosacea treated with doxycycline modified-release capsules in a randomized trial.
Di Nardo A; Holmes AD; Muto Y; Huang EY; Preston N; Winkelman WJ; Gallo RL
J Am Acad Dermatol; 2016 Jun; 74(6):1086-92. PubMed ID: 26951940
[TBL] [Abstract][Full Text] [Related]
16. Regulation of kallikrein-related peptidases in the skin - from physiology to diseases to therapeutic options.
Fischer J; Meyer-Hoffert U
Thromb Haemost; 2013 Sep; 110(3):442-9. PubMed ID: 23446429
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Spink6 in mouse skin: the conserved inhibitor of kallikrein-related peptidases is reduced by barrier injury.
Fischer J; Wu Z; Kantyka T; Sperrhacke M; Dimitrieva O; Koblyakova Y; Ahrens K; Graumann N; Baurecht H; Reiss K; Schröder JM; Proksch E; Meyer-Hoffert U
J Invest Dermatol; 2014 May; 134(5):1305-1312. PubMed ID: 24352040
[TBL] [Abstract][Full Text] [Related]
18. Reduction in serine protease activity correlates with improved rosacea severity in a small, randomized pilot study of a topical serine protease inhibitor.
Two AM; Hata TR; Nakatsuji T; Coda AB; Kotol PF; Wu W; Shafiq F; Huang EY; Gallo RL
J Invest Dermatol; 2014 Apr; 134(4):1143-1145. PubMed ID: 24213369
[No Abstract] [Full Text] [Related]
19. Antimicrobial and protease inhibitory functions of the human cathelicidin (hCAP18/LL-37) prosequence.
Zaiou M; Nizet V; Gallo RL
J Invest Dermatol; 2003 May; 120(5):810-6. PubMed ID: 12713586
[TBL] [Abstract][Full Text] [Related]
20. Doxycycline and chemically modified tetracyclines inhibit gelatinase A (MMP-2) gene expression in human skin keratinocytes.
Uitto VJ; Firth JD; Nip L; Golub LM
Ann N Y Acad Sci; 1994 Sep; 732():140-51. PubMed ID: 7978787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
